Cantor Fitzgerald
Exagen Prices $60.1M Public Offering of Stock
The company said it plans to use the proceeds to develop multiomics capabilities, including building out its clinical laboratory.
HTG Molecular Diagnostics Files for $20M Stock Offering
The Tucson, Arizona-based company previously raised $20 million through a public offering of its shares and a purchase deal with certain investors.
Cantor Fitzgerald Downgrades PerkinElmer to Neutral
The investment bank, which maintained its $60 price target for the company's stock, said it is looking for signs of revenue acceleration.
Cantor Fitzgerald Initiates Coverage of NeoGenomics at Overweight
The investment bank said NeoGenomics' acquisition of Clarient last year boosted the company into a leadership position in the cancer diagnostics market.